SS-31 (Elamipretide): What the Evidence Actually Shows

SS-31 — also called elamipretide, or MTP-131 in some older literature — is sold in the peptide-research market as a mitochondria-targeted antioxidant peptide. Unlike almost everything else in this site's non-board corpus, it is also a real drug in active clinical development by Stealth BioTherapeutics, and a live check of FDA's own approval database found something this article did not expect going in: elamipretide received real FDA accelerated approval in September 2025, for a specific, narrow, ultra-rare-disease use — on evidence considerably smaller and less rigorous than the negative trial this same compound also has for a different condition. This article reports both halves of that record directly.

What it actually is

Elamipretide is a small, mitochondria-targeting peptide developed to concentrate specifically in the inner mitochondrial membrane, where it binds cardiolipin — a phospholipid central to mitochondrial energy production — and is proposed to stabilize mitochondrial structure and function under conditions of oxidative stress. Stealth BioTherapeutics has developed it across several real, distinct clinical programs: Barth syndrome (an ultra-rare, X-linked genetic mitochondrial disorder), primary mitochondrial myopathy, and dry age-related macular degeneration. All three are covered directly below, at the evidence strength each actually earned.

The real finding: FDA accelerated approval, September 2025

Checked directly against openFDA's own Drugs@FDA database, elamipretide received a real, original FDA approval on September 19, 2025 — application NDA215244, brand name Forzinity, sponsor Stealth BioTherapeutics⁵. This is confirmed independently by a peer-reviewed drug-approval summary published months later: "In September 2025, elamipretide was granted accelerated approval in the USA for use to improve muscle strength in adult and pediatric patients with Barth syndrome weighing ≥ 30 kg. With this accelerated approval, elamipretide became the first disease-specific treatment approved for Barth syndrome¹." Read that indication at the precision the label itself uses, because it matters: Forzinity's own current DailyMed label states, "This indication is approved under accelerated approval based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint... Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial⁶." That is a narrow, single-disease, surrogate-endpoint approval — not a general verdict that elamipretide "works," and this article treats it exactly that narrowly rather than letting the headline fact of FDA approval imply more than the label itself claims.

The evidence behind that approval — real, and genuinely small

The pivotal efficacy data behind Forzinity's approval is worth reading at its actual size rather than assumed to be a large trial because it earned FDA approval. A retrospective, non-randomized comparison matched 8 patients continuously treated with elamipretide in the open-label extension of the TAZPOWER trial against 19 untreated "natural history control" patients using a propensity-score model². The results were real and statistically significant: a 79.7-meter improvement on the 6-minute walk test at week 64 (P=0.0004) and a 91.0-meter improvement at week 76 (P=0.0005), plus real gains in muscle strength by handheld dynamometry². Those are genuine, positive findings — and they come from 8 treated patients compared against an untreated historical cohort, not a randomized, blinded, placebo-controlled trial. That is precisely the kind of evidence FDA's accelerated-approval pathway exists to act on for diseases this rare, and it is also precisely the kind of evidence that requires the "confirmatory trial" condition the label itself states.

The honest contrast: a much larger, better-designed trial for a different use failed

This is the finding that keeps this article from reading as a simple approval story, and it needs to sit directly next to the approval above, not in a separate section a reader might skip. MMPOWER-3 — a real, phase 3, randomized, double-blind, PLACEBO-CONTROLLED trial, more than 20 times the size of the Barth syndrome evidence base above — tested elamipretide in 218 patients with primary mitochondrial myopathy, a different (though related) group of mitochondrial diseases³. The result, read directly from the paper: elamipretide did not meet either primary endpoint. The difference in 6-minute walk test distance between elamipretide and placebo was -3.2 meters (95% CI -18.7 to 12.3, P=0.69) — statistically indistinguishable from no effect — and the difference in total fatigue score was likewise not significant (P=0.37)³. The paper's own classification of evidence states this in the strongest terms a clinical trial paper uses: "Class I evidence that elamipretide does not improve the 6MWT or fatigue at 24 weeks compared with placebo in patients with primary mitochondrial myopathy³." This is the single largest, best-designed, most rigorous human trial of elamipretide located for this article, and it is a negative result, for a related-but-different disease than the one that got approved on much smaller data.

A third real trial adds a similarly nuanced data point. ReCLAIM-2, a randomized, placebo-controlled, double-masked trial in 176 patients with dry age-related macular degeneration, also missed both of its co-primary endpoints (change in low-luminance visual acuity and change in geographic-atrophy area)⁴. But it found a real, nominally significant secondary signal: a 43% reduction in progression of complete ellipsoid-zone loss and a 47% reduction in partial ellipsoid-zone degradation versus placebo (both P<0.005) — a surrogate marker for photoreceptor damage — plus significantly more patients gaining at least 10 letters of visual acuity (14.6% vs. 2.1%, P=0.0404)⁴. Reported at the precision the trial's own authors used: the primary endpoints were not met, and a real, statistically significant secondary signal was.

Why this site doesn't build a calculator to Forzinity's own label

Forzinity, the actual FDA-approved product, ships as a ready-to-use aqueous solution — 280mg per 3.5mL (80mg/mL) — in single-patient-use vials, confirmed directly from its own current label's Dosage Forms and Strengths section⁶. It requires no reconstitution. But a live check of the U.S. peptide-research grey market during this article's authoring found something genuinely different: five independent vendor listings, cross-checked, consistently and almost exclusively sell "SS-31" as a 10mg or 20mg lyophilized powder vial, reconstituted with bacteriostatic water before subcutaneous injection — a different real-world product, at a different concentration, from the FDA-approved solution. Our reconstitution calculator is built for that grey-market lyophilized-vial product this site's calculator engine models for every other compound — not for Forzinity's own pre-mixed formulation or FDA-labeled dose, and the calculator page itself states that distinction directly.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell SS-31/elamipretide — this site's own identity-layer research confirms it is not tagged to any reviewed seller. This compound sits in a genuinely unusual place in this corpus: a real, current, FDA-approved drug (Forzinity) exists for a specific, ultra-rare disease, granted on small, non-randomized comparative data through the accelerated-approval pathway — while the largest, most rigorous randomized trial of the same molecule, for a different (though related) mitochondrial disease, found no benefit at all. A third trial, for yet another indication, missed its primary endpoints but found a real secondary signal. None of that evidence — positive, negative, or mixed — was generated for, or applies to, the unregulated lyophilized research-peptide vials actually sold under this compound's name in the U.S. market, which are a genuinely different formulation from the approved drug discussed throughout this article.